VRTX

Nasdaq

VERTEX PHARMACEUTICALS INC / MA

Health Care, Biotechnology

$496.07

close 7 Aug 2026

+32.48%

52-week change

$125.68B

market cap

$362.50

$533.67

52-week range

Valuation

Market cap$125.68B

P/E (TTM / 5y avg)28.89x27.80x

Forward P/E (FY2026 / FY2027)26.28x22.94x

PEG (TTM / fwd)4.721.81

P/S (TTM)9.98x

P/B6.21x

EV/EBITDA (TTM)—

FCF yield (TTM)3.02%

Cash flow & dividend

FCF (TTM)$3.80B

FCF per share (TTM)$14.98

FCF margin (TTM)30.16%

Dividend yield (indicated / 5y avg)——

Annualized dividend—

Payout ratio (EPS / FCF)——

Growth & quality

Revenue YoY, latest Q+12.45%

Diluted EPS YoY, latest Q+8.02%

Operating margin (TTM)37.95%

Net margin (TTM)35.00%

ROE (latest FY)21.18%

Net debt / EBITDA (TTM)—

Interest coverage (TTM)—

Price

+155.23%+20.69%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +14.10%10Y CAGR +27.80%

Diluted EPS

5Y CAGR +8.29%

FCF per share

5Y CAGR +1.73%

Operating cash flow

5Y CAGR +2.22%

Free cash flow

5Y CAGR +1.30%

Operating margin

FCF margin

Return on equity

Return on capital employed

Shares outstanding

5Y CAGR -0.46%10Y CAGR +0.31%

Net debt / EBITDA

Interest coverage

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date2 Nov 2026

EPS estimate$5.04

Revenue estimate$3.41B

Last reported

Date—

EPS——

Revenue——